N | 72 |
Age (years) | 17.4 ± 4.8 |
Adolescents | 74% |
Men | 49% |
Duration of diabetes (years) | 8.1 ± 5.5 |
Full-scale intelligence quotient | 104.9 ± 13.1 |
State anxiety score at euglycemia | 32.9 ± 8.1 |
Subjects elevated anxiety scores at euglycemia | 53% |
State anxiety score at hypoglycemia | 35.8 ± 10.5 |
Blood glucose at euglycemia (mmol/l) | 5.85 ± 0.5 |
Blood glucose at hypoglycemia (mmol/l) | 3.28 ± 0.2 |
Subjects estimating blood glucose accurately (±10%) at euglycemia | 38% |
Subjects estimating blood glucose accurately (±10%) at hypoglycemia | 28% |
HbA1c (%) | 8.6 ± 1.4 |
Mean epinephrine increase at hypoglycemia (pmol/l) | 707 ± 1,092 |
Subjects with clinically elevated epinephrine | 34% |
Mean pancreatic polypeptide increase at hypoglycemia (pmol/l) | 68.5 ± 127.4 |
Subjects with clinically elevated pancreatic polypeptide | 42% |
For all subjects: | |
Autonomic symptom score at euglycemia | 0.8 ± 1.3 |
Autonomic symptom score at hypoglycemia | 1.6 ± 2.2 |
Subjects reporting increased autonomic symptoms at hypoglycemia | 42% |
Neuroglycopenic symptom score at euglycemia | 0.4 ± 0.8 |
Neuroglycopenic symptom score at hypoglycemia | 0.9 ± 1.6 |
Subjects reporting increased neuroglycopenic symptoms at hypoglycemia | 29% |
For “reliable reporters”: | |
Autonomic symptom score at euglycemia (N = 62) | 0.6 ± 1.2 |
Autonomic symptom score at hypoglycemia | 1.8 ± 2.3 |
Neuroglycopenic symptom score at euglycemia (N = 66) | 0.3 ± 0.8 |
Neuroglycopenic symptom score at hypoglycemia | 1.0 ± 1.7 |
N | 72 |
Age (years) | 17.4 ± 4.8 |
Adolescents | 74% |
Men | 49% |
Duration of diabetes (years) | 8.1 ± 5.5 |
Full-scale intelligence quotient | 104.9 ± 13.1 |
State anxiety score at euglycemia | 32.9 ± 8.1 |
Subjects elevated anxiety scores at euglycemia | 53% |
State anxiety score at hypoglycemia | 35.8 ± 10.5 |
Blood glucose at euglycemia (mmol/l) | 5.85 ± 0.5 |
Blood glucose at hypoglycemia (mmol/l) | 3.28 ± 0.2 |
Subjects estimating blood glucose accurately (±10%) at euglycemia | 38% |
Subjects estimating blood glucose accurately (±10%) at hypoglycemia | 28% |
HbA1c (%) | 8.6 ± 1.4 |
Mean epinephrine increase at hypoglycemia (pmol/l) | 707 ± 1,092 |
Subjects with clinically elevated epinephrine | 34% |
Mean pancreatic polypeptide increase at hypoglycemia (pmol/l) | 68.5 ± 127.4 |
Subjects with clinically elevated pancreatic polypeptide | 42% |
For all subjects: | |
Autonomic symptom score at euglycemia | 0.8 ± 1.3 |
Autonomic symptom score at hypoglycemia | 1.6 ± 2.2 |
Subjects reporting increased autonomic symptoms at hypoglycemia | 42% |
Neuroglycopenic symptom score at euglycemia | 0.4 ± 0.8 |
Neuroglycopenic symptom score at hypoglycemia | 0.9 ± 1.6 |
Subjects reporting increased neuroglycopenic symptoms at hypoglycemia | 29% |
For “reliable reporters”: | |
Autonomic symptom score at euglycemia (N = 62) | 0.6 ± 1.2 |
Autonomic symptom score at hypoglycemia | 1.8 ± 2.3 |
Neuroglycopenic symptom score at euglycemia (N = 66) | 0.3 ± 0.8 |
Neuroglycopenic symptom score at hypoglycemia | 1.0 ± 1.7 |
Data are means ± SD unless otherwise indicated.